We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women (CAPS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01052051
First Posted: January 20, 2010
Last Update Posted: September 13, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Joan Lappe, Creighton University
  Purpose
To determine the effect of increasing serum 25(OH)D from prevailing levels with vitamin D3 supplementation, while maintaining adequate calcium intake, on incidence of all-type cancer in a population sample of healthy postmenopausal women.

Condition Intervention Phase
Cancer Dietary Supplement: Vitamin D Dietary Supplement: Calcium Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women

Resource links provided by NLM:


Further study details as provided by Joan Lappe, Creighton University:

Primary Outcome Measures:
  • The primary outcome measure will be a cancer diagnosis. [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • Determine whether the achieved level of serum 25OHD at the end of year one of study predicts risk of cancer over four years [ Time Frame: 5 years ]
    The secondary outcome will be cancer diagnosis.

  • The secondary outcomes will be: 1. cancers: breast, lung, colon, myeloma, leukemia, lymphoma and 2. hypertension, cardiovascular disease, osteoarthritis, colonic adenomas, diabetes, upper respiratory infections, fractures and falls. [ Time Frame: 5 years ]

Enrollment: 2303
Study Start Date: June 2009
Study Completion Date: August 2015
Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: calcium
Daily calcium supplementation
Dietary Supplement: Calcium
Calcium 1200mg / daily
Experimental: Vitamin D
Daily Calcium and Vitamin D supplementation
Dietary Supplement: Vitamin D
Vitamin D 2000 IU/daily

Detailed Description:

Hypotheses:

Primary: Increasing serum 25(OH)D from prevailing levels with vitamin D3 supplementation, while maintaining adequate calcium intake, will significantly decrease incidence of all-type cancer in a population sample of healthy postmenopausal women.

Secondary:

  1. Increasing serum 25(OH)D from prevailing levels will significantly decrease incidence of specific cancers: breast, lung, colon, myeloma, leukemia, lymphoma.
  2. Increasing serum 25OHD from prevailing levels will significantly decrease incidence of other disorders, specifically hypertension, cardiovascular disease, osteoarthritis, colonic adenomas, diabetes, upper respiratory infections and falls.

Specific Aims:

  1. Determine the effect of supplementation with vitamin D3 on incidence of all types of cancer combined.
  2. Determine in a nested-case control study the association of serum 25OHD collected at randomization and at the end of year one of study with risk of cancer over four years.
  3. Sample randomly the population of healthy independently-living postmenopausal women 55 years and older from twelve adjacent rural counties in Nebraska.
  4. Enroll a random sample of 2300 women into an intervention study, assign them randomly to one of two treatment groups: 1) vitamin D3 (2000 IU/d) and calcium (1500 mg/d), or 2) vitamin D3 placebo and calcium placebo, and to follow each study participant for four years.
  5. Collect and store blood serum and white blood cells from every participant to test for genetic markers should the intervention be found effective in decreasing the incidence of cancer. Markers selected will be determined by the state of the science at the time of analysis.
  6. Determine the effect of supplementation with calcium and vitamin D3 on incidence of specific cancers: breast, lung, colon, myeloma, leukemia, and lymphoma.
  7. Determine the effect of supplementation on incidence of other disorders, specifically hypertension, cardiovascular disease, osteoarthritis, colonic adenomas, diabetes, upper respiratory infections, fractures, and falls.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age: ≥ 55 years
  • Last menstrual period (LMP): ≥ 4 years
  • Good general health
  • Willingness to participate in this 4 year long study
  • Able to give informed consent
  • Able to live independently and travel to the Fremont Area Medical Center (FAMC) for study visits

Exclusion Criteria:

  • History of cancer except

    • Superficial basal or squamous cell carcinoma of the skin
    • Other malignancies treated curatively more than 10 years ago
  • History of renal calculi or chronic kidney disease
  • History of sarcoidosis
  • History of tuberculosis
  • Participation in the previous Creighton cancer prevention study
  • Mini-Mental Status Exam (MMSE) score of ≤ 23. Use the MMSE if there are any concerns about the person's cognitive abilities or ability to give fully informed consent to the study. Concerns may be related to a person's lack of orientation to person, place, or time; language difficulties (inability to structure simple, complete sentences); or short term memory. The Hartford Institute for Geriatric Nursing recommends that a score of 23 or lower indicates cognitive impairment. (Accessed at www.harforddign.org). See appendix.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01052051


Locations
United States, Nebraska
Fremont Area Medical Center
Fremont, Nebraska, United States, 68025
Sponsors and Collaborators
Creighton University
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Investigators
Principal Investigator: Joan M Lappe, PhD Creighton University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Joan Lappe, Professor of Medicine, Creighton University
ClinicalTrials.gov Identifier: NCT01052051     History of Changes
Other Study ID Numbers: CAPS08-15024
R01CA129488-01A2 ( U.S. NIH Grant/Contract )
First Submitted: January 19, 2010
First Posted: January 20, 2010
Last Update Posted: September 13, 2016
Last Verified: October 2015

Additional relevant MeSH terms:
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Calcium, Dietary
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents